{"id":6805,"date":"2026-11-05T13:32:09","date_gmt":"2026-11-05T13:32:09","guid":{"rendered":"https:\/\/www.ahmetozyigit.com\/?p=6805"},"modified":"2026-11-05T16:26:08","modified_gmt":"2026-11-05T16:26:08","slug":"zayiflama-igneleri-hakkinda-bilinmesi-gerekenler","status":"publish","type":"post","link":"https:\/\/www.ahmetozyigit.com\/en\/zayiflama-igneleri-hakkinda-bilinmesi-gerekenler\/","title":{"rendered":"Everything You Need to Know About Weight Loss Injections, From A to Z"},"content":{"rendered":"<figure class=\"wp-block-image aligncenter size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"890\" height=\"500\" src=\"https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/zayiflama-igneleri-bilinmesi-gerekenler.jpg\" alt=\"\" class=\"wp-image-6825\" srcset=\"https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/zayiflama-igneleri-bilinmesi-gerekenler.jpg 890w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/zayiflama-igneleri-bilinmesi-gerekenler-300x169.jpg 300w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/zayiflama-igneleri-bilinmesi-gerekenler-768x431.jpg 768w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/zayiflama-igneleri-bilinmesi-gerekenler-18x10.jpg 18w\" sizes=\"(max-width: 890px) 100vw, 890px\" \/><\/figure>\n\n\n  \r\n    \r\n<div id=\"wpj-jtoc\" class=\"wpj-jtoc wpj-jtoc--main  --jtoc-the-content --jtoc-theme-default-v3 --jtoc-title-align-left --jtoc-toggle-icon --jtoc-toggle-chiclet --jtoc-toggle-embossed --jtoc-toggle-position-right --jtoc-toggle-1 --jtoc-has-numeration --jtoc-numeration-legacy --jtoc-header-as-toggle --jtoc-headings-full-row-clickable --jtoc-reading-time --jtoc-has-custom-styles --jtoc-is-folded --jtoc-animate --jtoc-align-left\" >\r\n  <!-- TOC -->\r\n        <div class=\"wpj-jtoc--toc wpj-jtoc--toc-inline\" >\r\n              <div class=\"wpj-jtoc--header\">\r\n        <div class=\"wpj-jtoc--header-main\">\r\n                    <div class=\"wpj-jtoc--title\">\r\n                        <span class=\"wpj-jtoc--title-label\">Yaz\u0131 \u0130\u00e7eri\u011fi<\/span>\r\n          <\/div>\r\n          <div class=\"wpj-jtoc--reading-time\"><span><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"16\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.75\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"lucide lucide-clock-icon lucide-clock\"><circle cx=\"12\" cy=\"12\" r=\"10\" \/><path d=\"M12 6v6l4 2\" \/><\/svg>50 minutes reading time<\/span><\/div>                      <div class=\"wpj-jtoc--toggle-wrap\">\r\n                                                          <div class=\"wpj-jtoc--toggle-box\">\r\n                  <div class=\"wpj-jtoc--toggle\"><\/div>\r\n                <\/div>\r\n                          <\/div>\r\n                  <\/div>\r\n      <\/div>\r\n            <div class=\"wpj-jtoc--body\">\r\n            <nav class=\"wpj-jtoc--nav\">\r\n        <ol class=\"wpj-jtoc--items\"><li class=\"wpj-jtoc--item --jtoc-h2\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h2\" data-depth=\"2\">\r\n                                                <a href=\"#bu-ilaclarin-etki-mekanizmasi-nedir\"  title=\"What is the mechanism of action of these drugs?\" data-numeration=\"1\">What is the mechanism of action of these drugs?\n<\/a>\r\n                    <\/div><ol class=\"wpj-jtoc--items\"><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#semaglutid-ozempic-wegovy\"  title=\"Semaglutide \u2013 Ozempic \/ Wegovy\" data-numeration=\"1.1\">Semaglutide \u2013 Ozempic \/ Wegovy\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#tirzepatid-mounjaro-zepbound\"  title=\"Tirzepatid \u2013 Mounjaro \/ Zepbound\" data-numeration=\"1.2\">Tirzepatid \u2013 Mounjaro \/ Zepbound\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#retatrutide-bir-sonraki-jenerasyon\"  title=\"Retatrutide: The Next Generation\" data-numeration=\"1.3\">Retatrutide: The Next Generation\n<\/a>\r\n                    <\/div><\/li><\/ol><\/li><li class=\"wpj-jtoc--item --jtoc-h2\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h2\" data-depth=\"2\">\r\n                                                <a href=\"#bu-igneleri-kullanirken-nasil-beslenmeliyiz\"  title=\"How should we eat while using these injections?\" data-numeration=\"2\">How should we eat while using these injections?\n<\/a>\r\n                    <\/div><ol class=\"wpj-jtoc--items\"><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#proteine-oncelik-verin\"  title=\"Prioritize protein!\" data-numeration=\"2.1\">Prioritize protein!\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#sebzeleri-ve-lifli-gidalari-artirin\"  title=\"Increase your intake of vegetables and fiber-rich foods.\" data-numeration=\"2.2\">Increase your intake of vegetables and fiber-rich foods.\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#rafine-seker-ve-karbonhidratlardan-uzak-durun\"  title=\"Avoid refined sugar and carbohydrates.\" data-numeration=\"2.3\">Avoid refined sugar and carbohydrates.\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#nisastayi-biraz-daha-akilli-tuketin\"  title=\"Consume starch a little more wisely.\" data-numeration=\"2.4\">Consume starch a little more wisely.\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#ultra-islenmis-gidalari-azaltin\"  title=\"Reduce ultra-processed foods.\" data-numeration=\"2.5\">Reduce ultra-processed foods.\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#aralikli-oruc-yaklasimi\"  title=\"Intermittent Fasting Approach\" data-numeration=\"2.6\">Intermittent Fasting Approach\n<\/a>\r\n                    <\/div><\/li><\/ol><\/li><li class=\"wpj-jtoc--item --jtoc-h2\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h2\" data-depth=\"2\">\r\n                                                <a href=\"#zayiflama-igneleri-kullanimi-esnasinda-ne-tur-egzersiz-yapilmali\"  title=\"What kind of exercise should be done while using weight loss injections?\" data-numeration=\"3\">What kind of exercise should be done while using weight loss injections?\n<\/a>\r\n                    <\/div><ol class=\"wpj-jtoc--items\"><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#zayiflama-igneleri-kullanirken-takviye-gerekir-mi\"  title=\"Do I need supplements when using weight loss injections?\" data-numeration=\"3.1\">Do I need supplements when using weight loss injections?\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#zayiflama-igneleri-omur-boyu-kullanilabilir-mi\"  title=\"Can weight loss injections be used for life?\" data-numeration=\"3.2\">Can weight loss injections be used for life?\n<\/a>\r\n                    <\/div><\/li><li class=\"wpj-jtoc--item --jtoc-h3\">\r\n        <div class=\"wpj-jtoc--item-content --jtoc-h3\" data-depth=\"3\">\r\n                                                <a href=\"#peki-bu-ilaclar-omru-uzatabilir-mi\"  title=\"So, can these medications prolong life?\" data-numeration=\"3.3\">So, can these medications prolong life?\n<\/a>\r\n                    <\/div><\/li><\/ol><\/li><\/ol>      <\/nav>\r\n          <\/div>\r\n      <\/div>\r\n    <\/div>\r\n\n\n\n<p class=\"wp-block-paragraph\">\n  Excess weight and obesity are not just an aesthetic problem. Obesity is a chronic metabolic disease that can increase the risk of developing insulin resistance, type 2 diabetes, high blood pressure, cholesterol disorders, fatty liver disease, sleep apnea, cardiovascular diseases, and some cancers. Therefore, the goal in obesity treatment is not just to lower the number on the scale. The main goals are to reduce fat mass while preserving muscle mass as much as possible, to improve blood sugar and insulin balance, to reduce cardiovascular risk, and to establish a healthy lifestyle in the long term.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Son y\u0131llarda kullan\u0131ma giren GLP-1 ve GLP-1\/GIP temelli tedaviler obezite tedavisinde \u00f6nemli bir de\u011fi\u015fim yaratm\u0131\u015ft\u0131r. Semaglutid ile yap\u0131lan STEP-1 \u00e7al\u0131\u015fmas\u0131nda 68 haftada ortalama yakla\u015f\u0131k %15, tirzepatid ile yap\u0131lan SURMOUNT-1 \u00e7al\u0131\u015fmas\u0131nda ise doza ba\u011fl\u0131 olarak 72 haftada yakla\u015f\u0131k %15\u201321 oran\u0131nda kilo kayb\u0131 g\u00f6zlemlenmi\u015ftir&nbsp;[1,2]. Bu rakamlar do\u011fru ki\u015filerde, do\u011fru dozlarda ve do\u011fru hayat tarz\u0131 de\u011fi\u015fiklikleri ile daha da yukar\u0131ya \u00e7\u0131kmakta ve uzun vadede neredeyse mide ameliyatlar\u0131 kadar kilo verdirebilmektedir. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  However, it is important to mention a crucial point here. These medications are not miraculous &quot;weight-loss injections.&quot; Calling them weight-loss injections is an oversimplification of these powerful biological agents. When used in the right patient, at the right dose, and in conjunction with a nutritional and exercise program, these treatments are powerful metabolic therapies that target the biological mechanisms of obesity.\n<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:clamp(16.834px, 1.052rem + ((1vw - 3.2px) * 0.716), 26px);\"><strong>What is the mechanism of action of these drugs?<\/strong>\n<\/h2>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Semaglutide \u2013 Ozempic \/ Wegovy<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Semaglutid bir&nbsp;GLP-1 resept\u00f6r agonistidir. V\u00fccudumuzda yemek sonras\u0131nda do\u011fal olarak salg\u0131lanan GLP-1 hormonunun etkilerini taklit eder. Ba\u015fl\u0131ca etkileri \u015funlard\u0131r:\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  &#8211; \u0130\u015ftah\u0131 azalt\u0131r.&nbsp;Beyindeki hipotalamus ve di\u011fer i\u015ftah d\u00fczenleyici merkezleri etkileyerek a\u00e7l\u0131k hissini azalt\u0131r ve tokluk hissini art\u0131r\u0131r.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  &#8211; Yeme davran\u0131\u015f\u0131n\u0131 etkiler.&nbsp;GLP-1 resept\u00f6rlerinin beynin \u00f6d\u00fcl ve motivasyon sistemleriyle de ili\u015fkisi vard\u0131r. \u00c7al\u0131\u015fmalar GLP-1 tedavisinin \u00f6zellikle yiyecekle ili\u015fkili \u00f6d\u00fcl yan\u0131tlar\u0131n\u0131 ve yiyecek arzusunu de\u011fi\u015ftirebildi\u011fini g\u00f6stermektedir&nbsp;[3]. GLP-1&#8217;in dopaminerjik \u00f6d\u00fcl devreleri dahil olmak \u00fczere birden fazla merkezi sinir sistemi yolunu mod\u00fcle etti\u011fi d\u00fc\u015f\u00fcn\u00fclmektedir.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  &#8211; Mide bo\u015falmas\u0131n\u0131 yava\u015flat\u0131r.&nbsp;\u00d6zellikle tedavinin ba\u015flang\u0131c\u0131nda yiyeceklerin mideden ince ba\u011f\u0131rsa\u011fa ge\u00e7i\u015fi yava\u015flayabilir. Bu durum daha uzun s\u00fcre tok hissetmemize yard\u0131mc\u0131 olur. Bu etkinin bir k\u0131sm\u0131 zaman i\u00e7erisinde azalabilir.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  &#8211; Kan \u015fekeri kontrol\u00fcn\u00fc iyile\u015ftirir.&nbsp;Kan \u015fekeri y\u00fckseldi\u011finde pankreastan ins\u00fclin salg\u0131lanmas\u0131n\u0131 destekler ve gereksiz glukagon salg\u0131s\u0131n\u0131 azalt\u0131r. Bu etkiler kan \u015fekerinin daha dengeli seyretmesine yard\u0131mc\u0131 olur.\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Tirzepatid \u2013 Mounjaro \/ Zepbound<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Tirzepatid bir ad\u0131m daha farkl\u0131 \u00e7al\u0131\u015f\u0131r. Tek bir resept\u00f6r yerine hem&nbsp;GLP-1 hem de GIP resept\u00f6rlerini&nbsp;aktive eder.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  GLP-1 \u00fczerinden aynen semaglutide, yani Ozempic&#8217;te oldu\u011fu gibi, i\u015ftah\u0131n azalmas\u0131, toklu\u011fun artmas\u0131, glukagonun d\u00fczenlenmesi ve mide bo\u015falmas\u0131n\u0131n yava\u015flamas\u0131 gibi etkiler ortaya \u00e7\u0131karken, GIP resept\u00f6r\u00fcn\u00fcn ek aktivasyonu ins\u00fclin yan\u0131t\u0131, ya\u011f dokusu metabolizmas\u0131 ve merkezi i\u015ftah kontrol\u00fc \u00fczerinde ilave etkiler sa\u011flar&nbsp;[2,4].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Bu \u00e7ift mekanizma tirzepatidin g\u00fcn\u00fcm\u00fczde mevcut en etkili farmakolojik kilo y\u00f6netimi se\u00e7eneklerinden biri olmas\u0131n\u0131 sa\u011flam\u0131\u015ft\u0131r. SURMOUNT-1 \u00e7al\u0131\u015fmas\u0131nda en y\u00fcksek doz grubunda ortalama kilo kayb\u0131 yakla\u015f\u0131k %21 olmu\u015f ve hastalar\u0131n yar\u0131s\u0131ndan fazlas\u0131 ba\u015flang\u0131\u00e7 kilosunun en az %20&#8217;sini kaybetmi\u015ftir&nbsp;[2].\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Retatrutide: The Next Generation<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Retatrutide, kilo verme tedavilerinde \u015fu anda en fazla dikkat \u00e7eken yeni molek\u00fcllerden biridir. Semaglutide yaln\u0131zca GLP-1 resept\u00f6r\u00fcn\u00fc, tirzepatide ise GLP-1 ve GIP resept\u00f6rlerini hedeflerken, retatrutide buna \u00fc\u00e7\u00fcnc\u00fc bir mekanizma daha ekleyerek&nbsp;GLP-1, GIP ve glukagon resept\u00f6rlerini ayn\u0131 anda aktive eder.&nbsp;Bu nedenle retatrutide bir \u201ctriple agonist\u201d, yani \u00fc\u00e7l\u00fc resept\u00f6r agonisti olarak tan\u0131mlanmaktad\u0131r.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  While appetite and glucose metabolism are controlled via GLP-1 and GIP, activation of the glucagon receptor has additional effects on energy expenditure and fat metabolism. Therefore, retatrutide was developed as a treatment that aims not only to make a person eat less, but also to simultaneously alter different aspects of energy metabolism and further stimulate fat burning. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Retatrutide&nbsp;<strong>It is not a drug that has yet received FDA approval.<\/strong>&nbsp;It is still in the research phase. However, the results from the Phase 3 program are quite strong, and the manufacturer plans to submit its FDA application in the first quarter of 2027. Therefore, if the approval process is successful, it is expected to become one of the options for obesity treatment in the near future.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Possible Side Effects<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The most common side effects of these drugs are related to the gastrointestinal system. Symptoms such as nausea, indigestion, bloating, constipation, or diarrhea may occur. However, a significant portion of these side effects are mild or moderate; they occur especially at the beginning of treatment and during dose escalation periods and decrease over time in most people [1,2]. Therefore, in treatment, not only which drug is used but also how the dose is increased is important.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Dr. Ahmet \u00d6zyi\u011fit&#8217;in klinik prati\u011finde geli\u015ftirdi\u011fi ki\u015fiye \u00f6zel doz protokollerinde ani ve b\u00fcy\u00fck doz art\u0131\u015flar\u0131ndan m\u00fcmk\u00fcn oldu\u011funca ka\u00e7\u0131n\u0131l\u0131r. Standart doz art\u0131rma protokollerinin aksine, gerekli g\u00f6r\u00fclen hastalarda daha k\u00fc\u00e7\u00fck ara dozlar kullan\u0131larak daha kademeli bir ge\u00e7i\u015f yap\u0131l\u0131r.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The primary goal here is not to raise the patient to the highest possible dose, but to find the lowest effective dose that provides sufficient results in terms of appetite control and weight loss, and to maintain that dose for as long as possible.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For example, the standard starting and escalating approach for tirzepatide (Mounjaro) treatment is 2.5 mg for the first 4 weeks, followed by 5 mg if necessary.<br><br>Week 1: 2.5 mg<br>Week 2: 2.5 mg<br>Week 3: 2.5 mg<br>Week 4: 2.5 mg<br>Week 5: 5 mg<br>Week 6: 5 mg<br>Week 7: 5 mg<br>Week 8: 5 mg<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br>In our clinical practice, doses are adjusted not according to a fixed pattern, but according to the individual&#039;s response to treatment. For example, a personalized dose escalation scheme for an average patient might proceed as follows:<br><br>Week 1: 2.5 mg<br>Week 2: 3 mg<br>Week 3: 3 mg<br>Week 4: 3.75 mg<br>Week 5: 3.75 mg<br>Week 6: 4.25 mg<br>Week 7: 4.25 mg<br>Week 8: 5 mg<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The aim of this approach is to minimize gastrointestinal side effects, particularly those associated with dose increases, by reducing sharp transitions between doses. Simultaneously, the patient&#039;s appetite control, satiety, and weight loss are closely monitored. If the current dose provides sufficient effect, it may be preferable to remain at the same dose rather than increasing it only as per the schedule. If the effect becomes insufficient, the dose can be increased in small increments according to the individual&#039;s needs.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The important point to remember is this: rapidly increasing the dose does not indicate treatment success. One of the fundamental principles in pharmacological treatment is to achieve the desired clinical effect with the lowest possible effective dose. To give a simple example; if one paracetamol tablet relieves your headache, taking four will not give you four times the benefit. On the contrary, you will be using an unnecessarily higher dose and increasing your risk of side effects. Our approach is similar in GLP-1\/GIP-based treatments. If a person&#039;s appetite is adequately controlled, portion sizes have decreased, they feel full, and they are losing weight at a healthy rate, it is not always necessary to increase the dose just because a certain week has arrived.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Therefore, appetite level, satiety duration, rate of weight loss, gastrointestinal tolerance, and other potential side effects are evaluated together throughout the treatment. Dose increases are only made when clinically necessary and to the extent required. In short, our goal is not the &quot;highest tolerated dose,&quot; but the lowest effective dose that provides sufficient clinical effect for the individual. Thus, we aim to make the treatment not only effective but also more sustainable and better tolerated.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  However, certain side effects may be observed in some patient groups. These can be primarily categorized as follows:\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Common side effects<\/strong> \u2013 yakla\u015f\u0131k her 10 ki\u015fiden 1&#8217;inden fazlas\u0131nda ilaca ve kullan\u0131lan doza g\u00f6re oranlar de\u011fi\u015fmekle birlikte:\n<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Nausea<\/li>\n\n\n\n<li>Diarrhea<\/li>\n\n\n\n<li>Constipation<\/li>\n\n\n\n<li>Vomiting<\/li>\n\n\n\n<li>Abdominal pain or discomfort<\/li>\n\n\n\n<li>Headache<\/li>\n\n\n\n<li>Indigestion may occur.<br><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\n  \u00d6rne\u011fin SURMOUNT \u00e7al\u0131\u015fmalar\u0131nda tirzepatid kullananlarda bulant\u0131 yakla\u015f\u0131k %25\u201329, ishal %19\u201323 civar\u0131nda g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Bunlar\u0131n b\u00fcy\u00fck b\u00f6l\u00fcm\u00fc hafif veya orta \u015fiddette olmu\u015f ve \u00f6zellikle doz art\u0131rma d\u00f6nemlerinde ortaya \u00e7\u0131km\u0131\u015ft\u0131r&nbsp;[2].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Less common problems<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Yakla\u015f\u0131k %1 d\u00fczeyinde veya birka\u00e7 y\u00fczde puanl\u0131k oranlarda; safra ta\u015f\u0131 veya safra kesesi problemleri, refl\u00fc, ge\u011firme, abdominal \u015fi\u015fkinlik ve enjeksiyon b\u00f6lgesi reaksiyonlar\u0131 g\u00f6r\u00fclebilir. Kesin s\u0131kl\u0131k kullan\u0131lan molek\u00fcle, doza, tedavi s\u00fcresine ve hasta \u00f6zelliklerine g\u00f6re de\u011fi\u015fir. \u00d6zellikle h\u0131zl\u0131 kilo kayb\u0131n\u0131n kendisi de safra ta\u015f\u0131 riskini art\u0131r\u0131r. B\u00fcy\u00fck bir randomize \u00e7al\u0131\u015fma meta-analizinde GLP-1 resept\u00f6r agonistlerinin safra kesesi ve safra yollar\u0131 hastal\u0131klar\u0131nda g\u00f6receli olarak bir miktar art\u0131\u015fla ili\u015fkili oldu\u011fu bulunmu\u015ftur. Mutlak risk art\u0131\u015f\u0131 ise \u00e7ok k\u00fc\u00e7\u00fckt\u00fcr&nbsp;[5].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Very rare but significant problems.<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Severe and persistent abdominal pain, especially if it radiates to the back and is accompanied by vomiting, warrants evaluation for acute pancreatitis. Allergic reactions are also very rare but require prompt intervention. Similarly, fluid loss due to severe vomiting or diarrhea is particularly important in individuals with kidney disease.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Does it increase the risk of pancreatitis?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Bu konuda ge\u00e7mi\u015fte \u00f6nemli endi\u015feler olu\u015fmu\u015ftur. Ancak bug\u00fcn elimizde bulunan randomize kontroll\u00fc \u00e7al\u0131\u015fmalar\u0131n toplu de\u011ferlendirmeleri semaglutid veya tirzapetidin&nbsp;akut pankreatit riskini anlaml\u0131 \u015fekilde art\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6stermemektedir.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  2024 y\u0131l\u0131nda 34.721 hastay\u0131 i\u00e7eren 21 randomize semaglutid \u00e7al\u0131\u015fmas\u0131n\u0131n meta-analizinde akut pankreatit a\u00e7\u0131s\u0131ndan semaglutid ile plasebo aras\u0131nda anlaml\u0131 bir risk art\u0131\u015f\u0131 bulunmam\u0131\u015ft\u0131r (OR 0,70; %95 GA 0,50\u20131,20)&nbsp;[6].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  This does not mean that pancreatitis is \u201cimpossible.\u201d Pancreatitis can very rarely occur during treatment, and suspicious symptoms should be taken seriously. The risk should always be considered in patients who have previously had pancreatitis. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Does it increase the risk of cancer?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Mevcut insan verileri GLP-1 resept\u00f6r agonistlerinin&nbsp;genel kanser riskini art\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6stermemektedir. 2025 y\u0131l\u0131nda yay\u0131mlanan 50 uzun s\u00fcreli randomize kontroll\u00fc \u00e7al\u0131\u015fman\u0131n meta-analizinde GLP-1 tedavileriyle toplam kanser riskinde art\u0131\u015f bulunmam\u0131\u015ft\u0131r&nbsp;[7].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Daha da ilgin\u00e7 olan, baz\u0131 g\u00f6zlemsel \u00e7al\u0131\u015fmalar obeziteyle ili\u015fkili baz\u0131 kanserlerde risk azalmas\u0131 olabilece\u011fini g\u00f6stermektedir. 1,6 milyondan fazla tip 2 diyabet hastas\u0131n\u0131n incelendi\u011fi 2024 tarihli bir \u00e7al\u0131\u015fmada GLP-1 kullananlarda ins\u00fclin kullananlarla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda pankreas kanseri dahil bir\u00e7ok obeziteyle ili\u015fkili kanser daha d\u00fc\u015f\u00fck oranda g\u00f6r\u00fclm\u00fc\u015ft\u00fcr&nbsp;[8].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Similarly, in a cohort study evaluating 86,632 people with obesity or overweight in 2025, those using GLP-1 had a lower overall cancer incidence; a trend toward reduced risk of pancreatic and breast cancer was also observed [9].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Dolay\u0131s\u0131yla bu ila\u00e7lar\u0131n pankreas veya meme kanserini&nbsp;\u00f6nledi\u011fini veya tedavi etti\u011fini s\u00f6ylemek i\u00e7in hen\u00fcz yeterli kan\u0131t olmasa mevcut insan verileri genel kanser riskinin artt\u0131\u011f\u0131n\u0131 desteklememetedir. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Where do the rumors about blindness come from?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Recently, there have been reports that GLP-1 group drugs may cause blindness. These reports are based on two different eye diseases: diabetic retinopathy and NAION (non-arteritic anterior ischemic optic neuropathy). \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Diyabetik retinopati, uzun y\u0131llar y\u00fcksek kan \u015fekeriyle ya\u015fayan ki\u015filerde g\u00f6z\u00fcn retina tabakas\u0131ndaki damarlar\u0131n hasar g\u00f6rmesiyle ortaya \u00e7\u0131kan bir hastal\u0131kt\u0131r. \u00d6zellikle kan \u015fekeri uzun s\u00fcredir kontrols\u00fcz seyreden ve mevcut diyabetik retinopatisi bulunan hastalarda, GLP-1 tedavisiyle kan \u015fekerinin \u00e7ok h\u0131zl\u0131 d\u00fc\u015fmesi, retinopatinin ge\u00e7ici olarak k\u00f6t\u00fcle\u015fmesine neden olabilir. Bu durum yaln\u0131zca GLP-1 ila\u00e7lar\u0131na \u00f6zg\u00fc de\u011fildir; kan \u015fekerini h\u0131zla d\u00fc\u015f\u00fcren di\u011fer etkili tedavilerde de g\u00f6r\u00fclebilmektedir. Semaglutid ile yap\u0131lan SUSTAIN-6 \u00e7al\u0131\u015fmas\u0131nda yakla\u015f\u0131k iki y\u0131ll\u0131k takip s\u00fcresince diyabetik retinopati komplikasyonlar\u0131 ila\u00e7 kullananlar\u0131n %3&#8217;\u00fcnde, plasebo grubunun ise %1,8&#8217;inde g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Ancak bu \u00e7al\u0131\u015fmadaki hastalar uzun s\u00fcredir diyabeti bulunan ve kardiyovask\u00fcler riski y\u00fcksek ki\u015filerdi. \u00dcstelik 2025 y\u0131l\u0131nda yay\u0131mlanan, yakla\u015f\u0131k 74.000 kat\u0131l\u0131mc\u0131y\u0131 kapsayan 78 randomize \u00e7al\u0131\u015fman\u0131n meta-analizinde semaglutidin genel olarak diyabetik retinopati riskini art\u0131rmad\u0131\u011f\u0131 g\u00f6zlemlenmi\u015ftir. K\u0131sacas\u0131 kontrols\u00fcz \u015feker d\u00fczeyleri olan ve diyabetik retinopatisi olan ki\u015filerde GLP-1 ila\u00e7lar\u0131ndan ziyade, h\u0131zl\u0131 \u015feker oynamalar\u0131ndan ka\u00e7\u0131nmak gerekir.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  \u0130kinci konu ise g\u00f6z sinirini besleyen dola\u015f\u0131m\u0131n bozulmas\u0131 sonucunda ani ve bazen kal\u0131c\u0131 g\u00f6rme kayb\u0131na neden olabilen NAION (Non-Arteritik Anterior \u0130skemik Optik N\u00f6ropati)&#8217;dir.  Baz\u0131 geni\u015f \u00e7apl\u0131 ara\u015ft\u0131rmalar semaglutid kullan\u0131m\u0131n\u0131n bu hastal\u0131\u011f\u0131n g\u00f6receli riskini yakla\u015f\u0131k iki kat art\u0131rabilece\u011fini g\u00f6stermi\u015ftir. Bunun \u00fczerine Avrupa \u0130la\u00e7 Ajans\u0131 (EMA), 2025 y\u0131l\u0131nda NAION&#8217;u semaglutidin \u00e7ok nadir g\u00f6r\u00fclen yan etkileri aras\u0131na eklemi\u015ftir. Ancak burada \u00f6nemli olan mutlak risktir: EMA&#8217;n\u0131n de\u011ferlendirmesine g\u00f6re semaglutid kullan\u0131m\u0131yla ili\u015fkili yakla\u015f\u0131k her 10.000 hasta-y\u0131l\u0131 ba\u015f\u0131na bir ilave NAION vakas\u0131 s\u00f6z konusudur. Yani g\u00f6receli risk art\u0131\u015f\u0131 dikkat \u00e7ekici g\u00f6r\u00fcnse de bu hastal\u0131\u011f\u0131n g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 olduk\u00e7a d\u00fc\u015f\u00fckt\u00fcr. Ayr\u0131ca bu bulgular\u0131n do\u011frudan Mounjaro (tirzepatid) dahil b\u00fct\u00fcn GLP-1 temelli ila\u00e7lar i\u00e7in ayn\u0131 \u00f6l\u00e7\u00fcde ge\u00e7erli oldu\u011fu s\u00f6ylenemez. Dolay\u0131s\u0131yla bu ila\u00e7lar\u0131n yayg\u0131n bi\u00e7imde k\u00f6rl\u00fc\u011fe neden oldu\u011fu y\u00f6n\u00fcndeki haberler bilimsel verileri do\u011fru yans\u0131tmamaktad\u0131r. Diyabeti olmayan, bilinen g\u00f6z hastal\u0131\u011f\u0131 bulunmayan ki\u015filerde diyabetik retinopatiyle ilgili risk de ayn\u0131 \u015fekilde de\u011ferlendirilmemelidir. Bununla birlikte mevcut diyabetik retinopatisi olan hastalar\u0131n tedavi \u00f6ncesinde ve s\u0131ras\u0131nda g\u00f6z kontrollerinin yap\u0131lmas\u0131, ani g\u00f6rme kayb\u0131 geli\u015fen ki\u015filerin ise vakit kaybetmeden g\u00f6z hekimine ba\u015fvurmas\u0131 gerekir. GLP-1 tedavilerinin kilo kontrol\u00fc, kan \u015fekeri d\u00fczenlenmesi ve uygun hasta gruplar\u0131nda kardiyovask\u00fcler riskin azalt\u0131lmas\u0131 a\u00e7\u0131s\u0131ndan kan\u0131tlanm\u0131\u015f faydalar\u0131 g\u00f6z \u00f6n\u00fcnde bulunduruldu\u011funda, bu nadir g\u00f6z komplikasyonlar\u0131 \u00e7o\u011fu hasta i\u00e7in tedaviden ka\u00e7\u0131nmay\u0131 gerektirecek d\u00fczeyde bir risk olu\u015fturmamaktad\u0131r.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>What is the warning sign regarding thyroid cancer?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors. This has not been shown to occur in humans in the same way, and there are no reported cases to date.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  B\u00fcy\u00fck \u0130skandinav kohort \u00e7al\u0131\u015fmas\u0131nda GLP-1 kullan\u0131m\u0131yla tiroid kanserinde belirgin bir art\u0131\u015f saptanmam\u0131\u015ft\u0131r&nbsp;[10]. Buna kar\u015f\u0131l\u0131k baz\u0131 randomize \u00e7al\u0131\u015fma meta-analizlerinde k\u00fc\u00e7\u00fck bir tiroid kanseri sinyali g\u00f6r\u00fclm\u00fc\u015ft\u00fcr; olay say\u0131lar\u0131n\u0131n \u00e7ok d\u00fc\u015f\u00fck olmas\u0131 nedeniyle riskin olup olmad\u0131\u011f\u0131 ve boyutu hakk\u0131nda kesin bir yarg\u0131ya varmak m\u00fcmk\u00fcn olmamakla birlikte, olas\u0131l\u0131k olarak bu riskin olduk\u00e7a d\u00fc\u015f\u00fck oldu\u011funu s\u00f6ylemek do\u011fru olur&nbsp;[7].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Because <strong>Semaglutide and tirzepatide are not recommended for use in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 (Multiple Endocrine Neoplasia Type 2) syndrome.<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Are Thyroid Nodules a Barrier to Treatment?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Hay\u0131r. Tek ba\u015f\u0131na tiroid nod\u00fcl\u00fcn\u00fcn bulunmas\u0131 GLP-1 tedavisine engel de\u011fildir. Tiroid nod\u00fclleri toplumda son derece yayg\u0131nd\u0131r. \u00d6nemli olan nod\u00fcl\u00fcn \u00f6zellikleridir. \u015e\u00fcpheli ultrason bulgular\u0131, h\u0131zla b\u00fcy\u00fcyen nod\u00fcl, y\u00fcksek kalsitonin veya med\u00fcller tiroid kanseri \u015f\u00fcphesi varsa tedavi \u00f6ncesinde ileri de\u011ferlendirme gerekir. S\u0131radan benign tiroid nod\u00fcl\u00fc, Hashimoto tiroiditi veya levotiroksin kullan\u0131m\u0131 kendi ba\u015f\u0131na GLP-1\/GIP tedavisine kontrendikasyon olu\u015fturmaz&nbsp;[10].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Effects on Cardiovascular Health<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Bu ila\u00e7lar\u0131n faydas\u0131 yaln\u0131zca kilo kayb\u0131yla s\u0131n\u0131rl\u0131 de\u011fildir. SELECT \u00e7al\u0131\u015fmas\u0131nda fazla kilolu veya obez, daha \u00f6nceden kardiyovask\u00fcler hastal\u0131\u011f\u0131 bulunan ancak diyabeti olmayan 17.604 ki\u015fi takip edilmi\u015ftir. Semaglutid kullananlarda kardiyovask\u00fcler \u00f6l\u00fcm, \u00f6l\u00fcmc\u00fcl olmayan kalp krizi veya \u00f6l\u00fcmc\u00fcl olmayan inmeden olu\u015fan birle\u015fik sonlan\u0131m noktas\u0131&nbsp;%20 oran\u0131nda daha d\u00fc\u015f\u00fck&nbsp;bulunmu\u015ftur&nbsp;[11].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Tirzepatid i\u00e7in de kardiyovask\u00fcler yararlar\u0131 destekleyen veriler giderek artmaktad\u0131r. \u00d6zellikle obezite ve korunmu\u015f ejeksiyon fraksiyonlu kalp yetersizli\u011fi bulunan hastalarda yap\u0131lan SUMMIT \u00e7al\u0131\u015fmas\u0131nda kardiyovask\u00fcler \u00f6l\u00fcm veya k\u00f6t\u00fcle\u015fen kalp yetersizli\u011fi birle\u015fik sonlan\u0131m\u0131nda anlaml\u0131 azalma g\u00f6r\u00fclm\u00fc\u015ft\u00fcr&nbsp;[12].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Therefore, considering GLP-1-based treatments solely as &quot;weight-loss drugs&quot; would be incomplete. They are suitable for use, and approved for use even for cardiovascular diseases alone, particularly in susceptible groups. \n<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:clamp(16.834px, 1.052rem + ((1vw - 3.2px) * 0.716), 26px);\"><strong>How should we eat while using these injections?<\/strong>\n<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\n  \u0130\u015ftah\u0131n azalmas\u0131 \u00f6nemli bir f\u0131rsatt\u0131r. Ancak&nbsp;daha az yemek, otomatik olarak daha sa\u011fl\u0131kl\u0131 beslenmek anlam\u0131na gelmez. Tedavi s\u0131ras\u0131nda ama\u00e7 m\u00fcmk\u00fcn oldu\u011funca besleyici, liften zengin ve yeterli protein i\u00e7eren yiyeceklerden olu\u015fan yeni bir beslenme d\u00fczeni olu\u015fturmakt\u0131r&nbsp;[13].\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Prioritize protein!<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  During weight loss, not only fat tissue but also some lean body mass can be lost. This is an expected part of weight loss. However, what is important here is how much of the total weight lost is from fat and how much is from lean tissue.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  \u00d6rne\u011fin, 100 kg a\u011f\u0131rl\u0131\u011f\u0131nda ve 40 kg kas k\u00fctlesine sahip bir ki\u015finin v\u00fccut a\u011f\u0131rl\u0131\u011f\u0131n\u0131n %40&#8217;\u0131 kastan olu\u015fmaktad\u0131r. Bu ki\u015fi 10 kg verdi\u011finde, kas k\u00fctlesinden 2 kg kaybetmi\u015fse geriye 38 kg kas kal\u0131r. Ancak toplam a\u011f\u0131rl\u0131\u011f\u0131 90 kg&#8217;a d\u00fc\u015ft\u00fc\u011f\u00fc i\u00e7in kas oran\u0131 %40&#8217;tan yakla\u015f\u0131k %42&#8217;ye y\u00fckselir. Yani ki\u015fi mutlak olarak bir miktar kas kaybetmi\u015f olsa bile, v\u00fccudundaki kas oran\u0131 artm\u0131\u015f olabilir. Fakat yine de kas kayb\u0131n\u0131n minimumda olmas\u0131, ve metabolik olarak bizim i\u00e7in \u00e7ok \u00f6nemli olan kas k\u00fctlesinin fazla miktarlarda kaybedilmemesi olduk\u00e7a \u00f6nemlidir. Bu nedenle yeterli protein al\u0131m\u0131 ve diren\u00e7 egzersizi \u00f6zellikle \u00f6nemlidir.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Protein requirements should be determined based on an individual&#039;s age, weight, kidney function, and activity level. Daily protein needs should be calculated individually, especially for those at risk of muscle loss. \n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Increase your intake of vegetables and fiber-rich foods.<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  During GLP-1 treatment, decreased appetite and reduced food intake can make it difficult to obtain adequate vitamins, minerals, and fiber. Therefore, including vegetables in meals is particularly important. Vegetables are valuable sources of vitamin C, folate, potassium, magnesium, and various antioxidant compounds. These micronutrients play a role in many physiological processes, from the normal functioning of the immune system to energy metabolism, muscle and nerve function, and the maintenance of cellular health. Especially during periods of rapid weight loss, attention should be paid not only to the amount of calories consumed but also to the nutritional value of the foods consumed. In other words, as quantity decreases, nutritional quality becomes more important. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Another important characteristic of vegetables is their dietary fiber content. Fiber not only regulates bowel movements but also contributes to the healthy functioning of the gut microbiota. Fermentable fibers, in particular, are used by certain beneficial bacteria living in the large intestine to convert them into short-chain fatty acids such as butyrate, acetate, and propionate. These substances play important roles in the energy metabolism of intestinal cells, the protection of the intestinal barrier, and the regulation of immune responses. Furthermore, depending on the type, fibrous foods can slow glucose absorption, limit post-meal blood sugar spikes, and help maintain a feeling of fullness. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Because GLP-1 injection therapy can slow gastric emptying, consuming large amounts of fiber at once may increase bloating, gas, and abdominal discomfort in some people. In the initial period, consuming well-cooked vegetables such as zucchini, carrots, and spinach can facilitate digestion and reduce discomfort. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Although legumes are highly nutritious, their fermentable carbohydrates can worsen digestive complaints, especially during the first weeks of treatment. Therefore, foods like chickpeas, dried beans, and lentils should be introduced into the diet gradually and in small portions, depending on the individual&#039;s digestive tolerance. A good approach, particularly at the beginning of treatment, might be to focus on a vegetable and protein-rich diet for 10 days, then gradually introduce legumes in small portions. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  As the digestive system responds to treatment, the amount of raw vegetables, legumes, and other fiber sources can be increased. Adequate fluid intake is also important for the positive effects of fiber on bowel function. The goal is not to consume as much fiber as possible, but to create a balanced diet that supports gut health, is rich in micronutrients, and is well tolerated by the individual&#039;s digestive system.\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Avoid refined sugar and carbohydrates.<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  During GLP-1 injection therapy, not only the quantity or calories of food consumed are important, but also its metabolic effects. Sugary drinks, sweets, white bread, pastries, and foods high in refined carbohydrates are generally digested more quickly due to their low fiber content, causing more pronounced increases in blood sugar. These increases stimulate insulin secretion from the pancreas. Especially in individuals with insulin resistance, frequent and high consumption of refined carbohydrates makes it difficult to maintain glycemic control, and the resulting fluctuations in blood sugar can lead to increased consumption of sweets and eating disorders. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  GLP-1 receptor agonists help improve glycemic control by increasing insulin secretion while suppressing glucagon secretion when blood sugar rises. However, the use of these medications does not negate the metabolic importance of diet. Limiting refined sugars and carbohydrates supports the metabolic improvement provided by treatment, especially in individuals with type 2 diabetes or insulin resistance, and helps develop healthier eating habits even after the injection treatment process is completed. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Another important characteristic of refined carbohydrates is that they often contain low fiber and few micronutrients despite their high energy density. Since appetite is significantly reduced during GLP-1 injection treatment, daily food intake will already be limited. In this case, frequent consumption of low-nutrient foods can prevent sufficient space for more valuable nutrients in terms of protein, vitamins, and minerals. In short, if you consume small amounts of food that is poor in quality and micronutrients, you will not only fail to obtain sufficient vitamins and minerals, but you will also feel weaker and more lethargic. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  However, it is not accurate to categorize all carbohydrates together. Fiber-rich carbohydrate sources such as oats, whole grains, and whole fruits also contain vitamins, minerals, and various bioactive compounds. The digestion and glycemic effects of these foods differ from those of products containing refined sugar. Therefore, the goal is not to eliminate carbohydrates entirely, but to reduce the consumption of foods with low nutritional value and high added sugar and refined carbohydrate content, and to shift towards higher-quality carbohydrate sources. Whole grains and fruits, in particular, make very positive contributions to our diet in small portions. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The long-term success of GLP-1 therapy depends not only on the weight lost during the treatment period but also on the sustainability of the dietary habits acquired during the treatment. Therefore, reducing refined sugar consumption should be considered not as a temporary dietary restriction, but as a permanent dietary habit that supports long-term metabolic health. The goal is not just to lose weight and look good while using injections, but to establish lasting healthy habits and live a healthier life even after discontinuing the injection treatment. \n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Consume starch a little more wisely.<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Pirin\u00e7 ve patates gibi ni\u015fastal\u0131 g\u0131dalar pi\u015firildikten sonra so\u011futuldu\u011funda ni\u015fastan\u0131n bir b\u00f6l\u00fcm\u00fc&nbsp;retrogradasyon&nbsp;ge\u00e7irerek diren\u00e7li ni\u015fastaya d\u00f6n\u00fc\u015f\u00fcr. \u00d6rne\u011fin pirinci pi\u015firdikten sonra yakla\u015f\u0131k 10-12 saat buzdolab\u0131nda saklay\u0131p ertesi g\u00fcn g\u00fcvenli \u015fekilde yeniden \u0131s\u0131tmak, taze pi\u015fmi\u015f pirince k\u0131yasla diren\u00e7li ni\u015fasta miktar\u0131n\u0131 art\u0131r\u0131r. Bu \u015fekilde t\u00fcketilen pirin\u00e7, patates gibi g\u0131dalar\u0131n klinik \u00e7al\u0131\u015fmalarda yemek sonras\u0131 glukoz yan\u0131t\u0131n\u0131 normal t\u00fcketime oranla azaltt\u0131\u011f\u0131 g\u00f6zlemlenmi\u015ftir&nbsp;[14,15].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  It&#039;s important to know that this method doesn&#039;t make rice or potatoes &quot;low-carb&quot;; it only slightly alters the digestive properties of starch. Therefore, consuming it in large quantities is not a good idea. \n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Reduce ultra-processed foods.<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Reduced appetite during treatment presents a significant opportunity to reorganize dietary habits. Packaged snacks, sugary drinks, processed desserts, and highly ultra-processed products should be eliminated from the daily diet as much as possible, and replaced with real foods rich in vegetables, quality protein, healthy fats, and fiber.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  So the main goal here is to switch to a healthier eating pattern now that our appetite has decreased, and to avoid processed foods that we normally consume when we feel hungry, by staying away from their consumption.\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Intermittent Fasting Approach<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Prolonged fasting can have both positive and negative effects on human metabolism. Factors determining the outcome are not just the duration of fasting, but also the individual&#039;s metabolic health, physical activity level, body composition, and daily energy and protein intake.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Our bodies utilize various metabolic mechanisms to maintain blood sugar levels and meet energy needs during periods of fasting. Chief among these is glycogen stored in the liver. Liver glycogen contributes to maintaining blood glucose, particularly during the initial hours of fasting. In an average adult, liver glycogen stores are approximately 80\u2013120 grams. However, this amount can vary depending on an individual&#039;s nutritional status, physical activity, and the content of their last meal.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  During approximately 12 hours of fasting, liver glycogen stores gradually decrease. Throughout the day, our bodies use both glucose and fatty acids for energy production. As the fasting period lengthens, insulin levels decrease, the release of free fatty acids from adipose tissue increases, and the relative contribution of fats to energy production rises. At the same time, the liver continues to produce new glucose from lactate, glycerol, and some amino acids through a mechanism called gluconeogenesis.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  This metabolic transition is important in terms of metabolic flexibility. Metabolic flexibility is the body&#039;s capacity to efficiently switch between carbohydrates and fats according to its energy needs and nutritional status. Increased fat oxidation during fasting is a natural part of this mechanism. Furthermore, the production of ketone bodies increases with prolonged fasting. In particular, during longer periods of fasting, some tissues, including the brain, utilize ketones more effectively, which can partially reduce the need for glucose and thus the need to produce glucose from proteins. This is one of the protective adaptations the body develops against prolonged fasting.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  On the other hand, prolonging periods of fasting beyond what is necessary can lead to negative consequences in some individuals. During fasting, not only fats but also amino acids that can be used in glucose production are metabolized. In particular, prolonged fasting combined with insufficient protein intake, significant calorie restriction, and physical inactivity can negatively affect muscle-protein balance, leading to a decrease in muscle mass over time. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Therefore, fasting periods of 12-16 hours can support fat burning, but longer fasting periods, if continuous, may prevent sufficient protein intake during very limited time periods throughout the day and could have negative consequences for muscle mass.\n<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:clamp(16.834px, 1.052rem + ((1vw - 3.2px) * 0.716), 26px);\"><strong>What kind of exercise should be done while using weight loss injections?<\/strong>\n<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\n  One of the things I particularly emphasize during GLP-1 based weight loss treatments is preserving muscle mass as much as possible. This is because when we lose weight, not all of the weight lost comes from fat tissue; with almost every weight loss, a certain amount of lean body mass is lost along with fat tissue. This is a physiological and expected situation to a certain extent. Muscle tissue already makes up a significant portion of our body weight, and during weight loss, our main goal is not to have the unrealistic expectation of &quot;losing no muscle at all,&quot; but rather to ensure that as much of the weight lost as possible comes from fat tissue and that muscle loss is kept to a minimum. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  \u00d6rne\u011fin toplam kilo kayb\u0131n\u0131n %70\u201380 veya daha fazlas\u0131n\u0131n ya\u011f dokusundan gelmesi, v\u00fccut kompozisyonunda belirgin bir iyile\u015fme anlam\u0131na gelir. Uygun beslenme ve \u00f6zellikle yeterli protein al\u0131m\u0131yla birlikte d\u00fczenli diren\u00e7 egzersizi yapabilen baz\u0131 ki\u015filerde ise kas k\u00fctlesini neredeyse tamamen korurken a\u011f\u0131rl\u0131kl\u0131 olarak ya\u011f kaybetmek m\u00fcmk\u00fcn olabilir; bu elbette ula\u015fmak istedi\u011fimiz en ideal senaryolardan biridir.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  This is why exercise is such a crucial complement to GLP-1 therapy. Resistance exercises, in particular, signal to the muscles, &quot;I still need this tissue,&quot; and support muscle protein synthesis during a calorie deficit, helping to preserve lean mass. When combined with adequate protein intake, daily activity, and aerobic exercise, the goal is not just to reduce the number on the scale, but to preserve muscle, strength, physical capacity, and metabolic health as much as possible while decreasing body fat percentage.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  When used correctly, weight loss injections are powerful treatment tools that can significantly reduce metabolic risks associated with obesity, going beyond simply achieving a lower body weight. Therefore, our goal should never be just &quot;weight loss.&quot; A well-planned GLP-1 treatment, combined with proper nutrition, adequate protein intake, resistance exercise, aerobic activity, and healthy lifestyle habits, should aim not just for a lighter weight, but for a healthier, stronger, and metabolically better body composition, as well as improvements in health parameters such as blood sugar, blood lipids, and fatty liver disease.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Kilo kayb\u0131 s\u0131ras\u0131nda kas k\u00fctlesini korumak tedavinin en \u00f6nemli par\u00e7alar\u0131ndan biri oldu\u011fu i\u00e7in yaln\u0131zca y\u00fcr\u00fcy\u00fc\u015f veya kardiyo egzersizleri yeterli bir koruma sa\u011flamayabilir. Tabi ki hareketin her t\u00fcrl\u00fcs\u00fc \u00f6nemlidir ve eskiden tamamen hareketsiz olan bir insan\u0131n sadece y\u00fcr\u00fcmeye bile ba\u015flamas\u0131 olduk\u00e7a \u00f6nemli bir ad\u0131md\u0131r. Fakat bu ilk ad\u0131mlar\u0131n ard\u0131ndan ki\u015finin egzersize biraz daha entegre olmas\u0131 ve&nbsp;diren\u00e7 egzersizini de program\u0131n bir par\u00e7as\u0131 yapmas\u0131 \u00f6nemlidir. Yeterli proteinle birlikte diren\u00e7 egzersizi ya\u011fs\u0131z k\u00fctlenin korunmas\u0131na yard\u0131mc\u0131 olur&nbsp;[13,16].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The most effective exercise is done with an experienced physiotherapist or personal trainer who meets the right criteria. An exercise routine tailored to the individual, their fitness level, and any orthopedic or chronic conditions they may have, minimizes the risk of injury and allows for better results in line with the individual&#039;s needs and goals.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  For someone who hasn&#039;t exercised regularly before, suddenly going to the gym five times a week can be challenging. It&#039;s best to start with two days a week, beginning with a light routine, and then gradually increasing the intensity based on progress and goals. If you don&#039;t have the time or financial resources to follow a structured exercise routine with a physiotherapist or personal trainer, you can start with simple exercises at home. If sticking to a disciplined program is difficult, you can at least do some basic exercises at home. At this point, even a simple consultation with a physiotherapist, sports physician, or personal trainer will be sufficient to create a suitable plan and reduce your risk of injury. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Egzersize yeni ba\u015flayan bir ki\u015finin ilk hedefi m\u00fcmk\u00fcn oldu\u011funca fazla egzersiz yapmak de\u011fil, v\u00fccudun temel hareket kal\u0131plar\u0131n\u0131 do\u011fru \u015fekilde \u00f6\u011frenmesini sa\u011flamak olmal\u0131d\u0131r. \u0130nsan v\u00fccudu g\u00fcnl\u00fck ya\u015famda kaslar\u0131n\u0131 birbirinden tamamen ba\u011f\u0131ms\u0131z \u015fekilde kullanmaz. Sandalyeden kalkarken yaln\u0131zca quadriceps&#8217;i, yerden bir \u015fey kald\u0131r\u0131rken yaln\u0131zca hamstring&#8217;i veya bir kap\u0131y\u0131 iterken yaln\u0131zca triceps&#8217;i kullanmay\u0131z. Kaslar\u0131m\u0131z, eklemlerimiz ve sinir sistemimiz birlikte \u00e7al\u0131\u015fan hareket zincirleri olu\u015fturur.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Therefore, prioritizing basic multi-joint movements such as squats, lunges, hip-hinges\/deadlifts, push-ups or presses, and rows in beginner programs is a logical approach. Multi-joint exercises are particularly efficient in time-constrained programs because they work more than one large muscle group in the same movement. Studies examining time-efficient resistance exercises also support prioritizing bilateral, multi-joint movements; including at least one lower body push, one upper body push, and one upper body pull in the program [18].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  For example, a squat isn&#039;t just a leg exercise. It requires the coordinated work of the hips, quadriceps, and trunk stabilizers. Similarly, a row engages not just a single back muscle, but also the latissimus dorsi, trapezius, rhomboids, posterior deltoid, elbow flexors, and grip muscles. One of the things I most often recommend to my patients who say they have limited time and don&#039;t have time for exercise is investing in a rowing machine. It&#039;s one of the exercises I frequently choose because it&#039;s generally less expensive than a treadmill and can activate many muscle groups simultaneously in a short amount of time.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  One of the greatest advantages of rowing is its ability to combine cardiovascular exercise with muscle activity in a single movement. With each pull, the legs generate force, the hips and torso help transmit this force, and the back and arms complete the movement. Therefore, unlike a light-paced walk where only the legs work repetitively, a short rowing session allows us to keep many large muscle groups in the upper and lower body active at the same time. When the resistance and tempo are adjusted to suit the individual&#039;s capacity, we raise the heart rate while also applying a mechanical load to the muscles.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  This is especially important for me during GLP-1 treatment. If a patient can only dedicate 10-15 minutes a day to exercise, spending that time on a rowing machine is far more efficient in terms of keeping the muscles active and spreading the exercise throughout the body than spending the same amount of time walking at a low pace on a treadmill. This doesn&#039;t mean walking is worthless, of course; on the contrary, being active and taking enough steps throughout the day is extremely valuable for both circulation and overall cardiovascular health. The point here is that if we want to get as much physiological stimulation as possible from a short 10-15 minute exercise session, rowing is a much more powerful option compared to walking.\n<\/p>\n\n\n\n<figure data-wp-context=\"{&quot;imageId&quot;:&quot;6aecb62d02cd6&quot;}\" data-wp-interactive=\"core\/image\" data-wp-key=\"6aecb62d02cd6\" class=\"wp-block-image aligncenter size-full wp-lightbox-container\"><img decoding=\"async\" width=\"1188\" height=\"1086\" data-wp-class--hide=\"state.isContentHidden\" data-wp-class--show=\"state.isContentVisible\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on--pointerdown=\"actions.preloadImage\" data-wp-on--pointerenter=\"actions.preloadImageWithDelay\" data-wp-on--pointerleave=\"actions.cancelPreload\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/kurek-cekme-hareketi-calisan-kaslar.png\" alt=\"\" class=\"wp-image-6809\" srcset=\"https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/kurek-cekme-hareketi-calisan-kaslar.png 1188w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/kurek-cekme-hareketi-calisan-kaslar-300x274.png 300w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/kurek-cekme-hareketi-calisan-kaslar-1024x936.png 1024w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/kurek-cekme-hareketi-calisan-kaslar-768x702.png 768w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/kurek-cekme-hareketi-calisan-kaslar-13x12.png 13w\" sizes=\"(max-width: 1188px) 100vw, 1188px\" \/><button\n\t\t\tclass=\"lightbox-trigger\"\n\t\t\ttype=\"button\"\n\t\t\taria-haspopup=\"dialog\"\n\t\t\tdata-wp-bind--aria-label=\"state.thisImage.triggerButtonAriaLabel\"\n\t\t\tdata-wp-init=\"callbacks.initTriggerButton\"\n\t\t\tdata-wp-on--click=\"actions.showLightbox\"\n\t\t\tdata-wp-style--right=\"state.thisImage.buttonRight\"\n\t\t\tdata-wp-style--top=\"state.thisImage.buttonTop\"\n\t\t>\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewbox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\" \/>\n\t\t\t<\/svg>\n\t\t<\/button><figcaption class=\"wp-element-caption\">Click on the image to enlarge.<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  It is important to note here that there is a significant difference between muscle activation and the mechanical loading required to increase muscle strength and hypertrophy. Regularly activating and using muscles can contribute to maintaining muscle function and lean body mass, especially during weight loss. However, if the goal is to increase muscle strength or create hypertrophy in muscle tissue, simply activating the muscle is not enough. This requires subjecting the muscle tissue to sufficient mechanical stress and progressively increasing the applied load over time. Therefore, while exercises like rowing are quite valuable for keeping numerous muscle groups active, supporting them with appropriate resistance exercises is a more effective approach when aiming to develop muscle mass and strength.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The ideal approach is to combine aerobic activities like rowing or brisk walking with progressive resistance exercises such as squats, rows, presses, deadlifts, or alternatives tailored to the individual, on specific days of the week. When done this way, GLP-1 treatment ceases to be merely a treatment that reduces the number on the scale; it becomes part of a more comprehensive metabolic health program aimed at prioritizing fat loss while preserving muscle mass, strength, cardiovascular capacity, and overall functionality as much as possible.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  We started with short walks and gradually increased our activity level. We did this for about a month. For a month, we aimed to be more active by walking 2-3 times a week. Then we added an activity like rowing 2-3 days a week, and improved our fitness level. After spending a few months developing our fitness and improving our cardiovascular system, we were ready to do more intense exercise. So, after a 3-month warm-up, we&#039;re ready to move on to more resistance training. At this point, let&#039;s talk about exercises that we can easily integrate into our lives with short workouts, without spending hours, and let&#039;s make a plan. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  At this point, it is pointless to try to suddenly transform someone who has not recently done resistance training or weightlifting into a performance athlete. Our first goal is to work the large muscle groups, in particular. This is especially important for someone who says, \u201cI only have 15-20 minutes a day.\u201d If time is limited, it is a more efficient starting strategy to spend the first few minutes with exercises that use many muscle groups at once, rather than devoting the first few minutes to small and isolated muscle groups [18,19].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Classical American College of Sports Medicine (ACSM) recommendations suggest that large muscle groups should be performed before small muscle groups, and multi-joint movements before single-joint movements [20]. One of the important reasons for this is to be able to perform more complex and high-strength movements without fatigue.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  However, it would be incorrect to interpret this as &quot;it&#039;s wrong to work smaller muscles first.&quot; One of the important factors in exercise sequencing is which movement we want to prioritize, and another is our goal. Higher performance is expected in exercises performed at the beginning of a workout. Therefore, if a particular muscle or movement is the primary target, it makes sense to place that exercise at the beginning of the program.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Therefore, the main reason I prioritize basic movements at the beginner level isn&#039;t because small muscles are unimportant, but because it allows you to work more muscle groups, more joints, and more fundamental movement patterns in a shorter period of time.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Would 10-15 minutes a day really work?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Here, what is important is not only how long a workout lasts, but also the total weekly exercise stimulus and its ability to be sustained regularly. In recent years, approaches called \u201cminimal dose resistance training\u201d and \u201cexercise snacking\u201d have been researched especially for this reason. Current data show that even very low-volume resistance exercises can provide significant improvements in muscle strength in individuals who have not previously done regular resistance exercise [19]. Therefore, it is extremely important and meaningful to establish a regular resistance exercise routine of 10\u201315 minutes a day rather than not starting exercise at all.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The World Health Organization also recommends that adults perform moderate to high-intensity muscle-strengthening activities involving all major muscle groups at least two days a week. It is also particularly recommended that individuals who do not exercise start with small amounts of physical activity and gradually increase the duration, frequency, and intensity over time [21]. Therefore, resistance training does not necessarily have to be a one-hour gym session two or three times a week. It can be started with smaller exercise routines. In fact, I particularly recommend starting this way. Because when you force a sedentary person to exercise for hours at a time, the sustainability of this exercise program may not be very long. Therefore, starting with small steps, requiring a 10-15 minute time investment that doesn&#039;t put too much strain on the individual, is something that everyone can do more easily. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>How can a 10-15 minute daily schedule be implemented?<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  A practical method is to divide the days into alternating upper and lower body parts. For example:\n<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monday<\/strong> \u2013 Upper body<\/li>\n\n\n\n<li><strong>Tuesday<\/strong> \u2013 Lower body<\/li>\n\n\n\n<li><strong>Wednesday<\/strong> \u2013 Walking or Rowing<\/li>\n\n\n\n<li><strong>Thursday<\/strong> \u2013 Upper body<\/li>\n\n\n\n<li><strong>Friday<\/strong> \u2013 Lower body<\/li>\n\n\n\n<li><strong>Saturday<\/strong> - Spade<\/li>\n\n\n\n<li><strong>Sunday<\/strong> \u2013 Rest<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Initially, 1\u20132 sets of approximately 10\u201315 repetitions per exercise may be sufficient. The resistance used should be adjusted according to the individual&#039;s capacity. Later, for example, after performing the same routine for a month, progressive loading can be applied: the weight used, the number of repetitions, the number of sets, or the difficulty of the exercise can be gradually increased over time. Different load and programming methods of resistance training are an important strategy for achieving muscle strength and muscle growth [22].\n<\/p>\n\n\n\n<figure data-wp-context=\"{&quot;imageId&quot;:&quot;6aecb62d03478&quot;}\" data-wp-interactive=\"core\/image\" data-wp-key=\"6aecb62d03478\" class=\"wp-block-image aligncenter size-full wp-lightbox-container\"><img decoding=\"async\" width=\"1536\" height=\"1024\" data-wp-class--hide=\"state.isContentHidden\" data-wp-class--show=\"state.isContentVisible\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on--pointerdown=\"actions.preloadImage\" data-wp-on--pointerenter=\"actions.preloadImageWithDelay\" data-wp-on--pointerleave=\"actions.cancelPreload\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/haftalik-calisma-programi.png\" alt=\"\" class=\"wp-image-6808\" srcset=\"https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/haftalik-calisma-programi.png 1536w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/haftalik-calisma-programi-300x200.png 300w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/haftalik-calisma-programi-1024x683.png 1024w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/haftalik-calisma-programi-768x512.png 768w, https:\/\/www.ahmetozyigit.com\/wp-content\/uploads\/2026\/11\/haftalik-calisma-programi-18x12.png 18w\" sizes=\"(max-width: 1536px) 100vw, 1536px\" \/><button\n\t\t\tclass=\"lightbox-trigger\"\n\t\t\ttype=\"button\"\n\t\t\taria-haspopup=\"dialog\"\n\t\t\tdata-wp-bind--aria-label=\"state.thisImage.triggerButtonAriaLabel\"\n\t\t\tdata-wp-init=\"callbacks.initTriggerButton\"\n\t\t\tdata-wp-on--click=\"actions.showLightbox\"\n\t\t\tdata-wp-style--right=\"state.thisImage.buttonRight\"\n\t\t\tdata-wp-style--top=\"state.thisImage.buttonTop\"\n\t\t>\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewbox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\" \/>\n\t\t\t<\/svg>\n\t\t<\/button><figcaption class=\"wp-element-caption\">Click on the image to enlarge.<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Here, dividing into upper-lower body is not a physiological necessity. A 2024 systematic review and meta-analysis comparing split and full-body resistance programs shows that when total training volume is equalized, the two approaches generally yield similar results in terms of muscle strength and hypertrophy [23]. Therefore, we can use the upper-lower system not because it is \u201csuperior\u201d, but because it makes it easier to organize 10\u201315 minutes of daily exercise.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  A simple start with walking, then activation of multiple muscle groups such as rowing, and then basic movements to be done for 10\u201315 minutes every day, with regularity and progressive increase in the number of repetitions or load over time, is a very strong model, especially for a sedentary person or someone new to exercise [18,19]. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  It is important to reiterate that the exercise examples and suggestions presented here are general recommendations for individuals who generally lead a sedentary lifestyle and have no known health problems or orthopedic limitations, aiming for a safe and gradual start to exercise. Each individual&#039;s health status, physical capacity, and exercise needs are different. Therefore, it is advisable for individuals with existing health problems, past injuries, chronic illnesses, or mobility limitations to undergo a medical evaluation and, if necessary, seek personalized advice from a physiotherapist or sports physician before starting a new exercise program.\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Do I need supplements when using weight loss injections?<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  There is no standard supplement list for everyone. Supplements should be determined based on an individual&#039;s diet, blood tests, bowel function, medications used, and comorbidities. Some supplements can be used to aid the function of injections, provide necessary supplementation due to reduced nutrition, and reduce potential side effects in the stomach and intestines. Remember that the following list is not a universal recommendation. Supplements are not applied equally to everyone, and individual differences must be considered. Using dietary supplements without a doctor&#039;s recommendation is not appropriate.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Guar Gum-Based Fiber Supplement:<\/strong>&nbsp;If sufficient fiber cannot be obtained through diet, approximately 5\u201310 grams of soluble\/prebiotic fiber can be added daily, starting with a low dose. Adequate water intake is important when supplementing with fiber. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Magnesium Glycinate or Citrate:<\/strong>&nbsp;It can be used in individuals with magnesium deficiency or insufficient intake. Magnesium glycinate is one of the well-tolerated options. It can be used in the 200-250 mg daily range, especially in cases of reduced dietary intake where insufficient magnesium intake may occur. It should not be used in individuals with impaired kidney function without consulting a doctor.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Multivitamin and mineral supplement:<\/strong>&nbsp;Scientific studies have shown that daily intake of a good multivitamin, especially for people over a certain age, has benefits particularly for brain function. Therefore, taking a good multivitamin supplement can be beneficial not only during weight loss processes but also at other times. Since there is a risk of not getting enough micronutrients during weight loss, a good multivitamin supplement can be considered during this period. \n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Digestive enzymes:<\/strong>&nbsp;Digestive enzymes are substances that help break down proteins, fats, and carbohydrates ingested with food and aid in their absorption from the intestines. During GLP-1 treatment, slowed gastric emptying and altered gastrointestinal motility may lead to digestive complaints such as bloating, gas, indigestion, early satiety, and constipation in some individuals. In patients experiencing such symptoms, digestive enzyme supplements can be considered a supportive option, particularly to alleviate bloating and gas related to food digestion. While the effectiveness of some enzymes in specific food intolerances has been demonstrated in scientific studies, clinical research on the effectiveness of general-purpose digestive enzyme supplements in addressing gastrointestinal complaints associated with GLP-1 treatment is still limited. Therefore, digestive enzymes should be considered as a support option for individuals with digestive complaints, rather than a necessary supplement for everyone using GLP-1. Furthermore, the use of these supplements is not limited to GLP-1 treatment; they can also be used by individuals experiencing specific digestive problems independently of treatment, by selecting the appropriate enzyme content.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Artichoke Extract or Bergamot<\/strong>Artichoke extract supplements are often considered as contributing to gallbladder health. Although there isn&#039;t enough scientific research in this area, the use of artichoke extract could be considered for certain individuals.\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>Can weight loss injections be used for life?<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Obesity is not simply a condition defined by excess weight; it is a chronic and recurring disease resulting from a combination of genetic, hormonal, metabolic, and environmental factors. Therefore, obesity treatment may need to continue for a long time in some individuals. While a one-year treatment may be sufficient for some patients, others may require much longer-term, even lifelong, medication to maintain weight control.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  We can compare this situation to the treatment of hypertension. A person diagnosed with high blood pressure usually doesn&#039;t stop treatment spontaneously after taking medication for three months and their blood pressure returning to normal. This is because normal blood pressure is often a result of the medication taking effect. Similarly, weight loss and improvement in metabolic parameters during GLP-1 treatment do not mean that the predisposition to obesity has been completely eliminated.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Following weight loss, certain biological adaptation mechanisms are activated in the body. Energy expenditure may decrease, hormonal signals related to hunger and satiety may change, and appetite may increase again. These mechanisms can make it difficult to maintain the lost weight. Indeed, scientific studies show that many patients regain a significant portion of the weight they lost over time after GLP-1 treatment is discontinued. This does not mean that the treatment has failed; it reflects the chronic and recurrent biological nature of obesity.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  However, this does not mean that everyone who starts GLP-1 treatment has to take medication for life. Individuals who adopt healthy eating habits, incorporate regular physical activity into their lives, preserve muscle mass, and establish a sustainable lifestyle that supports weight control during treatment can maintain their target weight without medication after reaching it. However, weight regain may occur in some patients even with lifestyle changes. Therefore, discontinuation of treatment should be evaluated on an individual basis, and weight monitoring should continue afterward.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  A similar approach is used in the treatment of hypertension. In some patients, particularly those where excess weight, inactivity, and high sodium intake play a significant role, weight loss, regular exercise, and a healthy diet can significantly lower blood pressure. In suitable patients, under the supervision of a physician, it may be possible to reduce or completely discontinue the dosage of blood pressure medication. However, this is not applicable to every hypertensive patient.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  Therefore, the main goal of GLP-1 treatment should not be simply to reach a certain number on the scale. The treatment process should also be considered a period in which dietary habits are improved, physical activity is increased, muscle mass is preserved, and long-term metabolic health is supported.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  The key is not whether to stop the medication as soon as possible or to use it for life, but to determine the most appropriate treatment approach that can maintain the health gains achieved in the long term. While some people can achieve this without medication, for others long-term pharmacological support may be the best option.\n<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-medium-font-size\"><strong>So, can these medications prolong life?<\/strong>\n<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\n  There is some very interesting, but still early, scientific data on this subject. In 2026...&nbsp;<em>Nature<\/em>&nbsp;dergisinde yay\u0131mlanan bir \u00e7al\u0131\u015fmada ileri ya\u015ftaki di\u015fi farelere semaglutid verilmesi ya\u015flanmayla ili\u015fkili baz\u0131 biyolojik de\u011fi\u015fiklikleri azaltm\u0131\u015f ve&nbsp;medyan ya\u015fam s\u00fcresini 742 g\u00fcnden 834 g\u00fcne \u00e7\u0131karm\u0131\u015ft\u0131r&nbsp;[26].\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  This is an important scientific finding, but the increase in lifespan in mice does not prove that semagglutinin also extends lifespan in humans. Much longer-term studies are needed to demonstrate this in humans. However, based on the available data, it is expected to have effects such as weight control, blood sugar balance, reduced risk of cardiovascular disease, protection against chronic diseases, and extending or improving the quality of life.\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dr. Ahmet \u00d6zyi\u011fit<\/strong>\u00a0MD, ABAARM<br><em>Anti-Aging and Regenerative Medicine Specialist<\/em><\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sources<\/strong>\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  1. Wilding, JPH, Batterham, RL, Calanna, S. et al. (2021) &#039;Once-weekly semaglutide in adults with overweight or obesity&#039;, The New England Journal of Medicine, 384(11), pp. 989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  2. Jastreboff, AM, Aronne, LJ, Ahmad, NN et al. (2022) &#039;Tirzepatide once weekly for the treatment of obesity&#039;, The New England Journal of Medicine, 387(3), pp. 205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  3. Dang, V., Sambuco, N., Yammine, L. and Versace, F. (2026) &#039;Do GLP-1 receptor agonists alter brain responses to reward-related cues? &#039;A systematic review&#039;, bioRxiv [Preprint]. https:\/\/doi.org\/10.64898\/2026.01.31.702984\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  4. Liu, Z., Yu, S., Jin, X. et al. (2025) &#039;The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: A review&#039;, Drug Design, Development and Therapy, 19, pp. 10383\u201310409. https:\/\/doi.org\/10.2147\/DDDT.S559919\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  5. He, L., Wang, J., Ping, F. et al. (2022) &#039;Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials&#039;, JAMA Internal Medicine, 182(5), pp. 513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  6. Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A. and Nogueira, JP (2024) &#039;Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis&#039;, Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n, 71(3), pp. 124\u2013132. https:\/\/doi.org\/10.1016\/j.endien.2024.03.012\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  7. Silverii, GA, Marinelli, C., Bettarini, C., Del Vescovo, GG, Monami, M. and Mannucci, E. (2025) &#039;GLP-1 receptor agonists and the risk for cancer: A meta-analysis of controlled randomized trials&#039;, Diabetes, Obesity and Metabolism, 27(8), pp. 4454\u20134468. https:\/\/doi.org\/10.1111\/dom.16489\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  8. Wang, L., Xu, R., Kaelber, DC and Berger, NA (2024) &#039;Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes&#039;, JAMA Network Open, 7(7), e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  9. Dai, H., Li, Y., Lee, Y.A. et al. (2025) &#039;GLP-1 receptor agonists and cancer risk in adults with obesity&#039;, JAMA Oncology, 11(10), pp. 1186\u20131193. https:\/\/doi.org\/10.1001\/jamaoncol.2025.2681\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  10. Pasternak, B. et al. (2024) &#039;Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study&#039;, BMJ, 385, e078225. https:\/\/doi.org\/10.1136\/bmj-2023-078225\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  11. Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M. et al. (2023) &#039;Semaglutide and cardiovascular outcomes in obesity without diabetes&#039;, The New England Journal of Medicine, 389(24), pp. 2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  12. Packer, M., Zile, MR, Kramer, CM et al. (2025) &#039;Tirzepatide for heart failure with preserved ejection fraction and obesity&#039;, The New England Journal of Medicine, 392(5), pp. 427\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa2410027\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  13. Mozaffarian, D., Agarwal, M., Aggarwal, M. et al. (2025) &#039;Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society&#039;, The American Journal of Clinical Nutrition, 122(2), pp. 344\u2013367. https:\/\/doi.org\/10.1016\/j.ajcnut.2025.04.023\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  14. Sonia, S., Witjaksono, F. and Ridwan, R. (2015) &#039;Effect of cooling of cooked white rice on resistant starch content and glycemic response&#039;, Asia Pacific Journal of Clinical Nutrition, 24(4), pp. 620\u2013625. https:\/\/doi.org\/10.6133\/apjcn.2015.24.4.13\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  15. Strozyk, S., Rogowicz-Frontczak, A., Pilacinski, S. et al. (2022) &#039;Influence of resistant starch resulting from the cooling of rice on postprandial glycemia in type 1 diabetes&#039;, Nutrition &amp; Diabetes, 12, article 21. https:\/\/doi.org\/10.1038\/s41387-022-00196-1\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  16. American Diabetes Association Professional Practice Committee for Obesity (2026) &#039;Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity&#039;, BMJ Open Diabetes Research &amp; Care, 13(Suppl. 1), e005729. https:\/\/doi.org\/10.1136\/bmjdrc-2025-005729\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  17. Rodr\u00edguez, M.\u00c1., Quintana-Cepedal, M., Cheval, B. et al. (2026) &#039;Effect of exercise snacks on fitness and cardiometabolic health in physically inactive individuals: Systematic review and meta-analysis&#039;, British Journal of Sports Medicine, 60(2), pp. 133\u2013141. https:\/\/doi.org\/10.1136\/bjsports-2025-110027\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  18. Iversen, VM, Norum, M., Schoenfeld, BJ and Fimland, MS (2021) &#039;No time to lift? &#039;Designing time-efficient training programs for strength and hypertrophy: A narrative review&#039;, Sports Medicine, 51, pp. 2079\u20132095. https:\/\/doi.org\/10.1007\/s40279-021-01490-1\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  19. Nuzzo, JL, Pinto, MD, Kirk, BJC and Nosaka, K. (2024) &#039;Resistance exercise minimal dose strategies for increasing muscle strength in the general population: An overview&#039;, Sports Medicine, 54(5), pp. 1139\u20131162. https:\/\/doi.org\/10.1007\/s40279-024-02009-0\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  20. Kraemer, W.J., Adams, K., Cafarelli, E. et al. (2002) &#039;American College of Sports Medicine position stand. &#039;Progression models in resistance training for healthy adults&#039;, Medicine &amp; Science in Sports &amp; Exercise, 34(2), pp. 364\u2013380. https:\/\/doi.org\/10.1097\/00005768-200202000-00027\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  21. World Health Organization (2020) WHO guidelines on physical activity and sedentary behavior. Geneva: World Health Organization. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240015128 (Accessed: 13 October 2026).\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  22. Currier, B.S., McLeod, J.C., Banfield, L. et al. (2023) &#039;Resistance training prescription for muscle strength and hypertrophy in healthy adults: A systematic review and Bayesian network meta-analysis&#039;, British Journal of Sports Medicine, 57(18), pp. 1211\u20131220. https:\/\/doi.org\/10.1136\/bjsports-2023-106807\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  23. Ramos-Campo, DJ, Benito-Peinado, PJ, Andreu-Caravaca, L., Rojo-Tirado, MA and Rubio-Arias, J.\u00c1. (2024) &#039;Efficacy of split versus full-body resistance training on strength and muscle growth: A systematic review with meta-analysis&#039;, Journal of Strength and Conditioning Research, 38(7), pp. 1330\u20131340. https:\/\/doi.org\/10.1519\/JSC.0000000000004774\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  24. Bull, FC, Al-Ansari, SS, Biddle, S. et al. (2020) &#039;World Health Organization 2020 guidelines on physical activity and sedentary behavior&#039;, British Journal of Sports Medicine, 54(24), pp. 1451\u20131462. https:\/\/doi.org\/10.1136\/bjsports-2020-102955\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  25. Aronne, L. J., Sattar, N., Horn, D. B. et al. (2024) &#039;Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial&#039;, JAMA, 331(1), pp. 38\u201348. https:\/\/doi.org\/10.1001\/jama.2023.24945\n<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\n  26. Feng, Y., Barthez, M., Wang, Y. et al. (2026) &#039;Late-life semaglutide treatment slows aging and extends lifespan in female mice&#039;, Nature, 657, pp. 469\u2013476. https:\/\/doi.org\/10.1038\/s41586-026-10940-7\n<\/p>","protected":false},"excerpt":{"rendered":"<p>Fazla kilo ve obezite yaln\u0131zca estetik bir problem de\u011fildir. Obezite; ins\u00fclin direnci, tip 2 diyabet, y\u00fcksek tansiyon, kolesterol bozukluklar\u0131, karaci\u011fer ya\u011flanmas\u0131, uyku apnesi, kalp-damar hastal\u0131klar\u0131 ve baz\u0131 kanserlerin geli\u015fme riskini art\u0131rabilen kronik bir metabolik hastal\u0131kt\u0131r. Bu nedenle obezite tedavisinde hedef yaln\u0131zca tart\u0131daki rakam\u0131 d\u00fc\u015f\u00fcrmek de\u011fildir. Ya\u011f k\u00fctlesini azalt\u0131rken kas k\u00fctlesini m\u00fcmk\u00fcn oldu\u011funca korumak, kan \u015fekeri [&hellip;]<\/p>","protected":false},"author":2,"featured_media":6823,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6805","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genel"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/posts\/6805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/comments?post=6805"}],"version-history":[{"count":12,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/posts\/6805\/revisions"}],"predecessor-version":[{"id":6830,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/posts\/6805\/revisions\/6830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/media\/6823"}],"wp:attachment":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/media?parent=6805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/categories?post=6805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/tags?post=6805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}